. 2021 Sep 1;25(9):701–707. doi: 10.5588/ijtld.21.0298

Table 2.

Safety of COVID-19 vaccines approved in Europe

	Comirnaty	Moderna	Vaxzvria	Janssen
AEs clinical trials, %
All	27	23.9	NA^*	17–35
Severe	<4	<20	2.1	1.7
Serious	0.6	0.6	0.9	0.6
AEs real-world data, n
Mild/moderate (A)	105,686	9,900	85,287	595
Severe (B)	56,209	10,227	115,294	989
Ratio (B/A), %	53	103	135	166
Most frequent local side-effect	Pain at injection site	Pain at injection site	Pain at injection site and tenderness	Pain at injection site
Most frequent systemic side-effects	Fatigue and headache	Fatigue and headache	Fatigue, headache, feverishness, and myalgia	Fatigue, headache, and myalgia
Total number of AEs reported to EudraVigilance, n^†	161,895	20,127	200,581	1,575
Number of CVST	48	4	260	11
Number of DVT	517	96	1,012	44
Number of pulmonary embolisms	866	231	1,281	68

^* This study could not obtain adverse reaction rate.³^,⁴^,⁸^,¹¹

^† Data from EudraVigilance database as of 1 May 2021.

AE = adverse event; NA = not available; CVST =cerebral venous sinus thrombosis; DVT = deep vein thrombosis.